Rare disease is one of the top therapeutic areas of drug development and investments in the US and Europe, supported by relatively high drug prices. Recently, there have been many exciting scientific and clinical breakthroughs in gene therapies for treating rare diseases. However in Asia, this is still a relatively nascent area for biotech companies. Why is this so, and what are future trends and opportunities in terms of business, scientific and clinical developments?
In this Zoom webinar organized by Esco Ventures X, expert speakers Prof. Harvey Lodish from Boston (MIT/Whitehead) will discuss the science of developing drugs for rare diseases, including novel modalities like gene therapy. A/Prof. Stacey Tay from the National University Hospital (NUH) Singapore will weigh in on the rare disease clinical landscape in Singapore and Southeast Asia. Yann Chong Tan from Esco Ventures will moderate the session and touch on the business opportunities, leveraging science from Singapore/Asia to develop rare diseases for the US/global market.